ADVFN
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc (SLRX)

0.678
-0.07
(-9.36%)
0.689
0.011
(1.62%)

Salarius Pharmaceuticals Inc (SLRX) Quote

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.689
( -7.89% )
Bid
0.65
Ask
0.6899
Volume
463,100
0.6406 Day's Range 0.721
0.4519 52 Week Range 7.20
Market Cap
Previous Close
0.748
Open
0.71
Last Trade Time
Financial Volume
$ 312,308
VWAP
0.674385
Average Volume (3m)
1,279,348
Shares Outstanding
2,127,286
Dividend Yield
-
PE Ratio
-0.26
Earnings Per Share (EPS)
-2.62
Revenue
-
Net Profit
-5.58M

About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Salarius Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SLRX. The last closing price for Salarius Pharmaceuticals was $0.75. Over the last year, Salarius Pharmaceuticals shares have traded in a share price range of $ 0.4519 to $ 7.20.

Salarius Pharmaceuticals currently has 2,127,286 shares outstanding. The market capitalization of Salarius Pharmaceuticals is $1.59 million. Salarius Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.26.

SLRX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.181-20.80459770110.870.890.6573209000.76334274CS
40.03960.651.330.6139688880.98397918CS
120.04737.371045659970.64171.330.609212793480.97910881CS
26-2.321-77.10963455153.013.530.45197781521.08249419CS
52-1.231-64.11458333331.927.20.451915596322.56569029CS
156-41.091-98.350885591241.7857.560.45196066705.9263283CS
260-263.311-99.73901515152647000.4519804443135.19734566CS

SLRX - Frequently Asked Questions (FAQ)

What is the current Salarius Pharmaceuticals share price?
The current share price of Salarius Pharmaceuticals is $ 0.689
How many Salarius Pharmaceuticals shares are in issue?
Salarius Pharmaceuticals has 2,127,286 shares in issue
What is the market cap of Salarius Pharmaceuticals?
The market capitalisation of Salarius Pharmaceuticals is USD 1.59M
What is the 1 year trading range for Salarius Pharmaceuticals share price?
Salarius Pharmaceuticals has traded in the range of $ 0.4519 to $ 7.20 during the past year
What is the PE ratio of Salarius Pharmaceuticals?
The price to earnings ratio of Salarius Pharmaceuticals is -0.26
What is the reporting currency for Salarius Pharmaceuticals?
Salarius Pharmaceuticals reports financial results in USD
What is the latest annual profit for Salarius Pharmaceuticals?
The latest annual profit of Salarius Pharmaceuticals is USD -5.58M
What is the registered address of Salarius Pharmaceuticals?
The registered address for Salarius Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Salarius Pharmaceuticals website address?
The website address for Salarius Pharmaceuticals is www.flex-pharma.com
Which industry sector does Salarius Pharmaceuticals operate in?
Salarius Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SQFTPresidio Property Trust Inc
$ 13.5299
(164.77%)
51.06M
TROOTROOPS Inc
$ 1.33
(104.62%)
93.35M
LBDAVLiberty Broadband Corporation
$ 91.86
(94.41%)
271
LBDKVLiberty Broadband Corporation
$ 90.65
(92.75%)
1.4k
SDSTStardust Power Inc
$ 0.4705
(86.71%)
386.3M
RYETRuanyun Edai Technology Inc
$ 1.72
(-91.49%)
13.23M
EDHLEverbright Digital Holding Ltd
$ 0.901
(-79.05%)
17.49M
INKTMiNK Therapeutics Inc
$ 40.64
(-36.67%)
5.05M
WKHSWorkhorse Group Inc
$ 2.80
(-36.65%)
12.17M
WHLRLWheeler Real Estate Investment Trust Inc
$ 96.13
(-36.55%)
252
SDSTStardust Power Inc
$ 0.4705
(86.71%)
386.3M
CANCanaan Inc
$ 0.9671
(34.24%)
191.41M
OPENOpendoor Technologies Inc
$ 0.9018
(15.76%)
159.32M
NVDANVIDIA Corporation
$ 164.07
(-0.52%)
136.98M
NCNANuCana PLC
$ 0.045701
(-8.96%)
123.8M

SLRX Discussion

View Posts
georgie18 georgie18 4 weeks ago
SLRX...$1.20...🥳
👍️0
glenn1919 glenn1919 3 months ago
SLRX........................................................a/h
👍️0
makinezmoney makinezmoney 4 months ago
$SLRX: popper....... $1.20

whats the deally yo

GO $SLRX
👍️0
Monksdream Monksdream 4 months ago
SLRX, new 52 week low
👍️0
Invest-in-America Invest-in-America 6 months ago
SLRX: NASDAQ now like the old Pre-Columbian OTC days!!!!
👍️0
maximus_art maximus_art 6 months ago
halt.. don't move
👍️0
glenn1919 glenn1919 6 months ago
SLRX..........................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 6 months ago
SLRX: On the Moon already, behind that MERGER news today, but hardly any iHub POSTS about it; maybe because merely one of those @SAGE-like 'BUY-OUTS' at a specific PRICE?? So it doesn't soar beyond that?? Just a stupid GUESS.)
👍️0
tw0122 tw0122 6 months ago
$1.85
👍️0
tw0122 tw0122 6 months ago
$1.79 low floater needs a little volume and off it goes $3.9-$3.73 target 
👍 1
tw0122 tw0122 6 months ago
 approval of the issuance of additional shares by our stockholders in accordance with the applicable stock exchange rules or (ii) the average price paid for all shares of common stock issued under the Purchase Agreement (including both Purchase Shares and Commitment Shares) is equal to or greater than $1.528, which is a price equal to the lower of (A) the Nasdaq Official Closing Price immediately preceding the execution of the Purchase Agreement and (B) the average Nasdaq Official Closing
👍️0
tw0122 tw0122 6 months ago
....This prospectus relates to the potential resale from time to time by C/M Capital Master Fund, LP, or the Selling Stockholder, of up to 6,733,334 shares of common stock, par value $0.0001 per share, or common stock. The shares of common stock to which this prospectus relates consists of shares that have been or may be issued by us to the Selling Stockholder pursuant to a Securities Purchase Agreement, dated as of December 12, 2024, by and between us and the Selling Stockholder, ...
👍️0
tw0122 tw0122 6 months ago

This prospectus relates to the potential resale from time to time by C/M Capital Master Fund, LP, or the Selling Stockholder, of up to 6,733,334 shares of common stock, par value $0.0001 per share, or common stock. The shares of common stock to which this prospectus relates consists of shares that have been or may be issued by us to the Selling Stockholder pursuant to a Securities Purchase Agreement, dated as of December 12, 2024, by and between us and the Selling Stockholder, or the Purchase Agreement, establishing an equity line of credit, or the Equity Financing. Such shares of our common stock include (i) up to 6,666,667 shares of common stock, or the Purchase Shares, that we may elect, in our sole discretion, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, to issue and sell to the Selling Stockholder, from time to time from and after the Commencement Date (as defined below) under the Purchase Agreement, and subject to applicable stock exchange rules (assuming the shares are sold at a price of $1.50 per share) and (ii) up to 66,667 shares of common stock, or the Commitment Shares, that may be issued to the Selling Stockholder in connection with related issuances and sales of Purchase Shares as consideration for the Selling Stockholder’s execution and delivery of the Purchase Agreement. The actual number of shares of our common stock issuable will vary depending on the then-current market price of shares of our common stock sold to the Selling Stockholder under the Purchase Agreement, but will not exceed the number set forth in the preceding sentences unless we file an additional registration statement under the Securities Act of 1933, as amended, or the Securities Act, with the Securities Exchange Commission, or the SEC, and we obtain the approval of the issuance of shares of common stock by our stockholders in accordance with the applicable stock exchange rules. Under the applicable rules of The Nasdaq Stock Market LLC, or Nasdaq, in no event may we issue to the Selling Stockholder shares of our common stock representing more than 19.99% of the total number of shares of common stock outstanding as of the date of the Purchase Agreement, unless (i) we obtain the approval of the issuance of such shares by our stockholders in accordance with the applicable stock exchange rules or (ii) the average price paid for all shares of common stock issued under the Purchase Agreement (including both Purchase Shares and Commitment Shares) is equal to or greater than $1.528, which is a price equal to the lower of (A) the Nasdaq Official Closing Price immediately preceding the execution of the Purchase Agreement and (B) the average Nasdaq Official Closing Price of our common stock for the five trading days immediately preceding the execution of the Purchase Agreement, as calculated in accordance with the rules of Nasdaq, such that the sales of such common stock to the Selling Stockholder would not count toward such limit because they are “at market” under applicable stock exchange rules. See “The Committed Equity Financing” for a description of the Purchase Agreement and “Selling Stockholder” for additional information regarding the Selling Stockholder.We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the shares of our common stock by the Selling Stockholder. Additionally, we will not receive any proceeds from the issuance or sale of any Commitment Shares. However, we may receive up to $10.0 million in aggregate gross 
proceeds from the sale of the shares of common stock to the Selling Stockholder under the Purchase Agreement, from time to time in our discretion, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, after the date the registration statement that includes this prospectus is declared effective and after satisfaction of other conditions in the Purchase Agreement. The actual proceeds from the Selling Stockholder may be less than this amount depending on the number of shares of our common stock sold and the price at which the shares of our common stock are sold.This prospectus provides you with a general description of such securities and the general manner in which the Selling Stockholder may offer or sell the securities. More specific terms of any securities that the Selling Stockholder may offer or sell may be provided in a prospectus supplement that describes, among other things, the specific amounts and prices of the securities being offered and the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus.The Selling Stockholder may offer, sell or distribute all or a portion of the shares of our common stock acquired under the Purchase Agreement and hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will bear all costs, expenses and fees in connection with the registration of the shares of our common stock, including with regard to compliance with state securities or “blue sky” laws. The timing and amount of any sales are within the sole discretion of the Selling Stockholder. The Selling Stockholder is an underwriter under the Securities Act with respect to the resale of shares held by it. Although the Selling Stockholder is obligated to purchase shares of our common stock under the terms and subject to the conditions and limitations of the Purchase Agreement to the extent we choose to sell such shares of our common stock to it (subject to certain conditions), there can be no assurances that we will choose to sell any shares of our common stock to the Selling Stockholder, or that the Selling Stockholder will sell any or all of the shares of our common stock, if any, purchased under the Purchase Agreement pursuant to this prospectus. The Selling Stockholder will bear all commissions and discounts, if any, attributable to its sale of shares of our common stock. See “Plan of Distribution.”You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities.Our common stock is listed on The Nasdaq Capital Market under the symbol “SLRX.” On December 12, 2024, the last reported sale price of our common stock on The Nasdaq Capital Market was $1.44 per share.We are a “smaller reporting company” as defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein, and may elect to comply with reduced public company reporting requirements in future filings. Please see “Prospectus Summary ? Implications of Being a Smaller Reporting Company.”
👍️0
glenn1919 glenn1919 6 months ago
slrx...............................https://stockcharts.com/h-sc/ui?s=slrx&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 6 months ago
Ready 
👍️0
tw0122 tw0122 6 months ago
Boom boom ready for liftoff again
👍️0
glenn1919 glenn1919 7 months ago
SLRX.......................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 9 months ago
SLRX......................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783
👍️0
dbcoop1 dbcoop1 9 months ago
I think AH. I was on the USS QNRX today and it was rising Beautifully, It stated a Halt to Upside so waited and the walls came tumbling
down. what a play action fake.
👍️0
Invest-in-America Invest-in-America 9 months ago
SLRX: Well, maybe a little MUSIC???

👍️0
Invest-in-America Invest-in-America 9 months ago
SLRX: And THERE it goes!!!
👍️0
tw0122 tw0122 10 months ago
Reverse split in June looks primed for another pump. Buy a few for the quick upcoming pump and dump show
👍️0
glenn1919 glenn1919 10 months ago
SLRX..................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783
👍️0
TheFinalCD TheFinalCD 11 months ago
MOON
👍️0
Monksdream Monksdream 11 months ago
SLRX 10Q due AUGUST 5
👍️0
Stockexpertpro Stockexpertpro 11 months ago
SLRX 500K Float FDA News Coming Watch for a WINT Type move to the upside trading under cash with FDA News Imment Trading under Cash with over 7$ per share
👍️0
glenn1919 glenn1919 12 months ago
SLRX.......................................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783
👍️0
TheFinalCD TheFinalCD 12 months ago
https://dilutiontracker.com/app/search/SLRX?a=dbb88c
👍️0
trader59 trader59 12 months ago
Brazen manipulation, computer generated wash trading. The O/S has turned over 100X's today. Don't get trapped with grossly overpriced stock.
👍️0
Awl416 Awl416 12 months ago
Yikes
👍️0
glenn1919 glenn1919 12 months ago
SLRX.........................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 12 months ago
SLRX..................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
SLRX new 52 week low
👍️0
PonkenPlonken PonkenPlonken 1 year ago
chart looks ready
👍️0
tw0122 tw0122 1 year ago
3.40s
👍️0
Monksdream Monksdream 1 year ago
SLRX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
SLRX 1 for 8 Monday 6/17
👍️0
Monksdream Monksdream 1 year ago
SLRX new 52 lo
👍️0
Monksdream Monksdream 2 years ago
SLRX new 52 week low
👍️0
Awl416 Awl416 2 years ago
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
👍️0
81vette 81vette 2 years ago
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders,announced 1/5/23,next greatest cure for cancer is possible>targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces that on December 27, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,535,603, titled “Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical Disorders Using Same.” The issued claims cover the composition of matter for novel molecular glue degraders including Salarius’ preclinical cereblon-binding compound, SP-3204, through September 2037.
Targeted protein degradation (TPD) takes advantage of the body’s own degradation system to promote the selective elimination of disease-causing proteins. The newly issued patent is based on the molecular glue eragidomide (CC-90009) that is known to target the degradation of GSPT1, a protein that is highly expressed in numerous cancers, including hematologic and solid tumors.
👍️0
81vette 81vette 2 years ago
got the bounce off 200ma @ $3.30 ,float rotated 1x in 1 hr wow!!!
👍️0
81vette 81vette 2 years ago
zero borrow,no shares to short,gap filled, summit speaking 26th
👍️0
81vette 81vette 2 years ago
2m float,target $70.00,institution 17%,vol 4Xs ave,#1on my scanner,world looking at it now
👍️0
81vette 81vette 2 years ago
nasdaq promo out,thinking about buying!!!
👍️0
urge2surge urge2surge 3 years ago
Top picks here would be $GMER $NILE $SNPX. Best reward to risk plays. Honorable mentions, $NBRI $PGAS $NXGT
I'm done posting on this board. But it's been nice communicating with you. I'm vested in all the above so maybe we'll continue on any of the other boards.
Good luck to you.
👍️0
corvatsch corvatsch 3 years ago
the return of money in the OTC due to the rise in inflation is interesting.
I am currently exposed on XBIO Xenetic Biosciences at Nasdaq.
I have a small position on a very risky OTC stock.
(SMFX) SAM TRADE. has an ongoing process for an undeclared license in Singapore., but if it resolves to a small fine, it could take off ....

p.s.
I will wait NVDA in the $ 140-150 area before a buy ..
👍️0
urge2surge urge2surge 3 years ago
They may have started with good intentions but only a very few small bios ever materialize into something of real substance. Most are just ATM plays, banking off of hopeful and or naive investors. Took me a long time to see the forest from the trees. Better late than never. I monitor a lot of stocks and when I see weak bios issuing ATM I make a point to never re enter. A private placement is the best case scenario. They don't deserve my wallet or attentions thereafter. Eventually, with the market showing no signs of reversing for years to come, if at all, most will be delisted or bk. You can only play the investors to a certain point. With investors running for the exits, they'll be soon finding themselves with shut doors, as most won't be able to stay off creditors or debt liabilities. Good.

At this point in the pre hyper inflation recession period, I'm seeing an early return of monies into the OTC sector. Fwiw, here's a decent article on a few reward to risk plays that actually might produce some stellar returns. I know I can use it. Ugh...

https://insiderfinancial.com/4-otc-stocks-to-boost-your-portfolio-cybl-dpls-gmer-lclp/183146/

Glta
👍️0
corvatsch corvatsch 3 years ago
you are 100% right ....
they are management to be arrested immediately, sucking shareholders' money on the hope of a cure. incompetent and thieves !!!
👍️0
urge2surge urge2surge 3 years ago
I've monitored this after making some coin a long time ago. Since then, been a dog and rightly so. Seeing a lot of small cap bios that have issued ATM at beaten down low stock prices. Why? Because they inherently have nothing of value to offer except sell shares, get a paycheck, and continue their facade. It's happening on a lot of these plays in this sector sad to say. Most should be delisted and or bought out primarily for the NOLS write offs to big pharma. Most of these dogs will and should fail. Anybody that knows anyone with cancer, knows that very little has changed beyond chemo and radiation. Despite all the monies supposedly spent on advancements, treatments haven't changed. Immunotherapy treatments are starting to gain treatment protocols, and experimental last ditch efforts on stem cells, but the majority is still chemo and radiation.
Anyways, I've sworn off these dead end oncology small bios, as little if any return on investments other than disappointments. I especially write off any that issue ATM at this sub $1 low of years prices. Looking at a reverse split followed by wash rinse and repeats. Corporate should be ashamed of themselves for terrible fiduciary management of shareholders monies. But they don't care. So vote with your wallet and find real companies with product and revenues. Let these dogs die as they should.
Glta
👍️0

Your Recent History

Delayed Upgrade Clock